Skip to main content
. 2021 Jan 7;16(1):27–35. doi: 10.1007/s11523-020-00784-0

Fig. 4.

Fig. 4

Maximum percent change from baseline in the sum of the longest diameters of target lesions as assessed by the investigators. a Combined phase III and phase IV treatment-naïve cohort sunitinib arm and b treatment-naïve cohort placebo arm from the phase III trial. CR complete response, NE not evaluable, PD progressive disease, PR partial response, SD stable disease